ScreenerHero

ZVRA Zevra Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · zevra.com
11.08USD+3.26%Mkt Cap: 657.97M $P/E: 12.04

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platf…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap657.97M USD
Enterprise Value417.11M USD
Revenue (TTM)136.07M USD
Gross Profit89.99M USD
Net Income (TTM)83.23M USD
Revenue/Share2.37 USD
Last Price11.08 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees61
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)12.04
P/E (Forward)9.97
PEG10.67
EV/EBITDA10.29
EV/Revenue3.07
P/S4.68
P/B2.93
EPS (TTM)0.92
EPS (Forward)1.08
52W Range
8.01044% of range14.96
52W High14.96 USD
52W Low8.010 USD
Profitability
Gross Margin84.52%
Oper. Margin42.30%
EBITDA Margin29.80%
Profit Margin78.17%
ROE53.82%
ROA29.23%
Growth
Revenue Growth53.30%
Earnings Growth-88.40%
Cash Flow & Leverage
Operating CF-1.60M USD
CapEx (TTM)835.00K USD
FCF Margin35.56%
FCF Yield7.35%
Net Debt-220.07M USD
Net Debt/EBITDA-5.43
Balance Sheet
Debt/Equity0.41
Current Ratio5.17
Quick Ratio5.02
Book Value/Sh3.67 USD
Cash/Share3.73 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateDec 28, 2020
Splits
Last Split1:16
Split DateDec 28, 2020
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)25.00 USD
Upside (mean)+125.6%
Target Range20.00 USD – 35.00 USD
20.00+125.6% to mean35.00
# Analysts9
Ownership
Shares Out.59.38M
Float53.90M
Insiders1.26%
Institutions77.55%
Short Interest
Short Ratio6.8d
Short % Float9.78%
Short % Out.9.66%
Shares Short5.74M
Short (prev mo.)6.47M
Technical
SMA 5011.35 (-2.4%)
SMA 20010.57 (+4.8%)
Beta0.98
S&P 52W Chg16.45%
Avg Vol (30d)919.01K
Avg Vol (10d)1.07M
Technical Indicators
RSI (14)47.2
MACD-0.2922
MACD Signal-0.2212
MACD Hist.-0.0709
BB Upper12.80 USD
BB Middle11.40 USD
BB Lower10.00 USD
BB Width24.52%
ATR (14)0.5008 USD
Vol Ratio (20d)0.98x